Ting Feng Tsai, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 6 carriers
- Office
- 1
Offices
1 location · Apex Cardiology of Silicon Valley A Medical Partnership · 3 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Hazel Hawkins Memorial Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
28 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tsai’s office at (408) 369-7500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Aetna Medicare Eagle (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Aetna Medicare Enhanced (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A118154 · Current
Licensed to practise in California · since 2011 · expires 2027-03-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$907,597
Medicare paid this office $907,597 for 889 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, inclisiran, 1 mg | 51 | $251,921 | None |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 109 | $110,578 | $914 |
| Return visit (30+ min) | 458 | $93,685 | $112 |
| Long return visit (40+ min) | 230 | $82,181 | $164 |
| Insertion of heart rhythm monitor under skin | 13 | $65,429 | $4,673 |
See all 36 services
| Injection, inclisiran, 1 mg | 51 | $251,921 | None |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 109 | $110,578 | $914 |
| Return visit (30+ min) | 458 | $93,685 | $112 |
| Long return visit (40+ min) | 230 | $82,181 | $164 |
| Insertion of heart rhythm monitor under skin | 13 | $65,429 | $4,673 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 244 | $50,578 | $195 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 44 | $42,545 | $109 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 181 | $39,987 | $220 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $32,099 | $107 |
| New patient visit (45+ min) | 123 | $17,443 | $142 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $15,471 | $152 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 28 | $13,793 | $63 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 332 | $11,485 | $14 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 70 | $11,133 | $78 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 101 | $7,052 | $67 |
| New patient visit (60+ min) | 32 | $6,096 | $190 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 96 | $6,036 | $60 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 16 | $3,869 | $242 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $3,451 | $246 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 43 | $3,334 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 38 | $3,174 | $25 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 110 | $2,772 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 167 | $2,529 | $14 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 31 | $2,450 | $79 |
| Programming of dual lead pacemaker system | 24 | $2,144 | $74 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 116 | $2,141 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $2,072 | $63 |
| Injection of drug or substance under skin or into muscle | 50 | $1,277 | $14 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,139 | $95 |
| Nuclear medicine study of heart muscle blood flow by pet | 31 | $806 | $26 |
| Injection, regadenoson, 0.1 mg | 36 | $712 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 27 | $286 | $11 |
| Anticoagulant management of patient taking warfarin | 14 | $253 | $7 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 14 | $187 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $176 | $13 |
| Ultrasonic guidance for blood vessel access | 12 | $145 | $12 |
Procedures Medicare counted
| Pacemaker insertion or repair | 12 | More than 63% of doctors who do this |
Who their Medicare patients are
889 Original Medicare patients in 2024. Average age 78 · Under 65 1% · 85 and older 22% · Women 57% · Also on Medicaid 8% · Health risk score 1.35. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 39% · Atrial fibrillation 37% · Diabetes 32% · Chronic kidney disease 27% · Heart failure 25% · Cancer 19% · Depression 18% · Stroke 18% · COPD 14% · Dementia 14%.
The office billed $1,792,513, Medicare allowed $1,170,111 and paid $907,597; for 32,269 services of 67 kinds; $252,633 of it was for drugs given in the office and $654,965 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 889 | 32,269 | 78 | 1.35 | $1,792,513 | $907,597 |
| 2023 | 883 | 5,195 | 78 | 1.30 | $1,392,085 | $619,911 |
| 2022 | 904 | 5,297 | 78 | 1.36 | $1,334,385 | $583,819 |
| 2021 | 775 | 5,365 | 78 | 1.33 | $1,429,590 | $624,322 |
| 2020 | 714 | 4,410 | 78 | 1.33 | $1,211,645 | $516,864 |
| 2019 | 787 | 4,354 | 77 | 1.52 | $1,086,005 | $421,904 |
| 2018 | 631 | 3,266 | 78 | 1.40 | $797,815 | $291,609 |
| 2017 | 576 | 2,947 | 78 | 1.59 | $728,445 | $269,783 |
| 2016 | 197 | 884 | 78 | 1.46 | $207,530 | $78,946 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 33 services
| Return visit (30+ min) | 486 | $107,625 | $114 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 104 | $100,049 | $953 |
| Insertion of heart rhythm monitor under skin | 17 | $84,396 | $4,964 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 248 | $51,391 | $202 |
| Long return visit (40+ min) | 165 | $48,535 | $166 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 181 | $41,365 | $227 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 115 | $31,502 | $109 |
| New patient visit (45+ min) | 163 | $22,621 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 108 | $17,017 | $148 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 58 | $15,391 | $32 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 68 | $10,819 | $78 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 38 | $7,275 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 96 | $6,438 | $65 |
| Injection, regadenoson, 0.1 mg | 34 | $6,051 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 92 | $5,736 | $60 |
| New patient visit (60+ min) | 28 | $5,512 | $197 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $5,197 | $400 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 13 | $4,003 | $308 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 22 | $3,693 | $23 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 43 | $3,506 | $82 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 45 | $3,283 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 41 | $3,033 | $26 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 12 | $2,973 | $248 |
| Programming of dual lead pacemaker system | 29 | $2,659 | $83 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 104 | $2,478 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 30 | $2,415 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 170 | $2,393 | $14 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 134 | $2,222 | $6 |
| Nuclear medicine study of heart muscle blood flow by pet | 43 | $1,164 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 30 | $341 | $11 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 20 | $273 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $271 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $258 | $13 |
2022: 35 services
| Return visit (30+ min) | 441 | $103,049 | $112 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 96 | $97,362 | $983 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 242 | $53,938 | $223 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 237 | $51,223 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 129 | $31,245 | $92 |
| Long return visit (40+ min) | 105 | $29,816 | $168 |
| New patient visit (45+ min) | 141 | $20,273 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $19,938 | $173 |
| Telephone medical discussion with physician, 21-30 minutes | 119 | $17,236 | $100 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 89 | $13,910 | $78 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 66 | $10,572 | $25 |
| Injection, regadenoson, 0.1 mg | 46 | $8,937 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 101 | $6,644 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 97 | $6,475 | $62 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 32 | $5,467 | $23 |
| New patient visit (60+ min) | 25 | $4,515 | $181 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 34 | $4,319 | $23 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,114 | $374 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 50 | $3,270 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 41 | $2,909 | $26 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 151 | $2,591 | $6 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $2,420 | $220 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 176 | $2,401 | $13 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 96 | $2,338 | $24 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 24 | $1,952 | $81 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,623 | $74 |
| Programming of dual lead pacemaker system | 15 | $1,607 | $85 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 17 | $844 | $50 |
| Evaluation of cardiac rhythm monitor system | 11 | $703 | $54 |
| Nuclear medicine study of heart muscle blood flow by pet | 24 | $647 | $27 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $435 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $318 | $11 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 18 | $267 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $172 | $13 |
| Ultrasonic guidance for blood vessel access | 12 | $141 | $12 |
2021: 31 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 117 | $102,035 | $797 |
| Return visit (30+ min) | 374 | $87,861 | $118 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 265 | $73,946 | $278 |
| Long return visit (40+ min) | 205 | $67,849 | $158 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 215 | $49,178 | $208 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $24,510 | $95 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 101 | $19,648 | $96 |
| New patient visit (45+ min) | 113 | $17,167 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $16,539 | $184 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 68 | $13,699 | $25 |
| Injection, regadenoson, 0.1 mg | 54 | $10,283 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 138 | $9,556 | $65 |
| New patient visit (60+ min) | 46 | $8,302 | $180 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 44 | $7,968 | $24 |
| Telephone medical discussion with physician, 21-30 minutes | 44 | $6,421 | $121 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $5,804 | $64 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $4,972 | $382 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 19 | $4,959 | $261 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 27 | $4,801 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 51 | $4,171 | $28 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 42 | $3,233 | $28 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 122 | $3,135 | $24 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 119 | $2,081 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 138 | $1,824 | $13 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,771 | $80 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 28 | $1,575 | $56 |
| Programming of dual lead pacemaker system | 14 | $1,143 | $76 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $797 | $72 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 43 | $493 | $11 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 25 | $361 | $14 |
| Ultrasonic guidance for blood vessel access | 20 | $252 | $13 |
2020: 30 services
| Long return visit (40+ min) | 238 | $84,635 | $136 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 272 | $66,053 | $243 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 76 | $61,589 | $790 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 205 | $48,222 | $210 |
| Return visit (30+ min) | 260 | $42,821 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $35,035 | $97 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 109 | $21,125 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $17,079 | $186 |
| New patient visit (60+ min) | 82 | $15,701 | $191 |
| Injection, regadenoson, 0.1 mg | 43 | $8,091 | None |
| Insertion of pacemaker and upper and lower heart chamber electrode | 17 | $7,997 | $470 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 116 | $7,885 | $64 |
| New patient visit (45+ min) | 52 | $7,313 | $141 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 67 | $4,765 | $68 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 28 | $4,410 | $25 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 20 | $2,995 | $24 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 122 | $2,910 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 120 | $2,511 | $16 |
| Ultrasound of both sides of head and neck blood flow | 12 | $2,140 | $178 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 13 | $2,124 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 36 | $1,960 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 27 | $1,774 | $51 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 67 | $1,679 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 29 | $1,632 | $29 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 11 | $1,217 | $87 |
| External ekg recording for more than 48 hours up to 21 days | 42 | $1,107 | $25 |
| Programming of dual lead pacemaker system | 15 | $949 | $59 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 42 | $936 | $21 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 32 | $372 | $11 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 20 | $309 | $15 |
2019: 30 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 272 | $64,866 | $235 |
| Long return visit (40+ min) | 171 | $58,180 | $137 |
| Return visit (30+ min) | 318 | $56,384 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 215 | $49,834 | $208 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 136 | $34,474 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 107 | $21,379 | $180 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 101 | $19,876 | $96 |
| New patient visit (45+ min) | 101 | $14,717 | $146 |
| New patient visit (60+ min) | 67 | $12,480 | $186 |
| Injection, regadenoson, 0.1 mg | 58 | $10,633 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 120 | $8,289 | $64 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 17 | $7,209 | $424 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $6,210 | $67 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 22 | $5,771 | $262 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 174 | $3,175 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 136 | $2,743 | $16 |
| Programming of dual lead pacemaker system | 24 | $2,169 | $57 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $2,072 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 21 | $1,992 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,983 | $66 |
| External ekg recording for more than 48 hours up to 21 days | 57 | $1,833 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 57 | $1,625 | $25 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,512 | $101 |
| Short return visit (20+ min) | 20 | $1,439 | $65 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 18 | $1,329 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 20 | $945 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 21 | $928 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 50 | $657 | $11 |
| Ultrasonic guidance for blood vessel access | 22 | $288 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $39 | $3 |
2018: 24 services
| Return visit (30+ min) | 296 | $58,364 | $92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 229 | $51,886 | $225 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 173 | $38,921 | $206 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $19,591 | $92 |
| New patient visit (45+ min) | 125 | $16,449 | $132 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 83 | $15,574 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $13,906 | $178 |
| Long return visit (40+ min) | 76 | $13,745 | $127 |
| Injection, regadenoson, 0.1 mg | 56 | $9,799 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 104 | $7,137 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 59 | $3,787 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,587 | $64 |
| Ultrasound of both sides of head and neck blood flow | 15 | $2,601 | $173 |
| Short return visit (20+ min) | 38 | $2,589 | $65 |
| New patient visit (60+ min) | 13 | $2,439 | $188 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 29 | $2,426 | $76 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 104 | $1,975 | $16 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 112 | $1,903 | $6 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 15 | $1,282 | $12 |
| Programming of dual lead pacemaker system | 18 | $1,251 | $54 |
| External ekg recording for more than 48 hours up to 21 days | 29 | $781 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 29 | $675 | $23 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $382 | $21 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $184 | $10 |
2017: 22 services
| Return visit (30+ min) | 237 | $48,369 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 151 | $36,817 | $230 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 123 | $32,740 | $262 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $29,048 | $92 |
| New patient visit (45+ min) | 152 | $21,762 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $20,075 | $178 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 57 | $11,068 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 135 | $8,203 | $58 |
| Injection, regadenoson, 0.1 mg | 42 | $7,288 | None |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,216 | $435 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $5,182 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 73 | $5,115 | $67 |
| Long return visit (40+ min) | 25 | $4,433 | $134 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 148 | $2,698 | $6 |
| Ultrasound of both sides of head and neck blood flow | 14 | $2,500 | $179 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 20 | $2,056 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 84 | $1,428 | $16 |
| Short return visit (20+ min) | 21 | $1,273 | $61 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,085 | $99 |
| Programming of dual lead pacemaker system | 15 | $1,028 | $54 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $321 | $20 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $229 | $11 |
2016: 14 services
| Return visit (30+ min) | 85 | $12,010 | $100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 42 | $9,940 | $231 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,441 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $7,037 | $93 |
| New patient visit (45+ min) | 41 | $6,103 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $6,044 | $64 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $5,560 | $505 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 41 | $2,693 | $57 |
| Long return visit (40+ min) | 16 | $2,558 | $135 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 11 | $2,099 | $95 |
| Short return visit (20+ min) | 17 | $1,167 | $69 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 65 | $1,078 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 14 | $1,007 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 32 | $514 | $16 |
Drugs they prescribed that Part D paid
$1,021,053
Pharmacies billed $1,021,053 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,539) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,579 generic and 960 brand-name prescriptions · $1,021,053 in drug cost · 32 antibiotic prescriptions to 27 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 502 | $529,414 | $1,055 |
| Xarelto | 74 | $98,180 | $1,327 |
| Entresto | 53 | $78,896 | $1,489 |
| Repatha Sureclick | 101 | $76,799 | $760 |
| Multaq | 53 | $60,494 | $1,141 |
See all 51 drugs
| Eliquis | 502 | $529,414 | $1,055 |
| Xarelto | 74 | $98,180 | $1,327 |
| Entresto | 53 | $78,896 | $1,489 |
| Repatha Sureclick | 101 | $76,799 | $760 |
| Multaq | 53 | $60,494 | $1,141 |
| Farxiga | 49 | $41,261 | $842 |
| Nexletol | 16 | $18,763 | $1,173 |
| Praluent | 19 | $13,591 | $715 |
| Brilinta | 14 | $8,096 | $578 |
| Rosuvastatin | 318 | $6,310 | $20 |
| Nebivolol | 80 | $5,788 | $72 |
| Atorvastatin | 373 | $4,391 | $12 |
| Metoprolol | 277 | $4,165 | $15 |
| Flecainide Acetate | 55 | $3,326 | $60 |
| Amlodipine Besylate | 421 | $2,745 | $7 |
| Amiodarone | 93 | $2,162 | $23 |
| Diltiazem 24hr Er (Cd) | 76 | $2,145 | $28 |
| Ezetimibe | 73 | $1,917 | $26 |
| Furosemide | 233 | $1,813 | $8 |
| Losartan | 220 | $1,710 | $8 |
| Spironolactone | 113 | $1,251 | $11 |
| Clopidogrel | 56 | $1,178 | $21 |
| Verapamil Er | 32 | $1,121 | $35 |
| Lisinopril | 154 | $1,115 | $7 |
| Valsartan | 23 | $1,048 | $46 |
| Metoprolol | 146 | $1,035 | $7 |
| Carvedilol | 115 | $906 | $8 |
| Potassium Chloride | 49 | $876 | $18 |
| Terazosin | 26 | $794 | $31 |
| Midodrine | 11 | $669 | $61 |
| Digoxin | 22 | $655 | $30 |
| Diltiazem 24hr Er | 11 | $558 | $51 |
| Sotalol | 34 | $539 | $16 |
| Bumetanide | 19 | $476 | $25 |
| Hydralazine | 53 | $472 | $9 |
| Valsartan-Hydrochlorothiazide | 13 | $449 | $35 |
| Pantoprazole | 27 | $420 | $16 |
| Hydrochlorothiazide | 77 | $383 | $5 |
| Diltiazem 24hr Er (Xr) | 13 | $356 | $27 |
| Metolazone | 21 | $338 | $16 |
| Isosorbide Mononitrate Er | 26 | $324 | $12 |
| Bisoprolol | 18 | $287 | $16 |
| Losartan-Hydrochlorothiazide | 18 | $256 | $14 |
| Prazosin | 15 | $253 | $17 |
| Dilt-Xr | 13 | $253 | $19 |
| Fenofibrate | 12 | $176 | $15 |
| Minoxidil | 14 | $131 | $9 |
| Atenolol | 18 | $123 | $7 |
| Clonidine | 17 | $117 | $7 |
| Cephalexin | 17 | $53 | $3 |
| Benazepril | 12 | $41 | $3 |
Year by year
| 2024 | 4,539 | 619 | 0% (0) | 21% | $1,021,053 |
| 2023 | 4,015 | 552 | 0% (0) | 25% | $1,069,022 |
| 2022 | 3,645 | 499 | 0% (0) | 21% | $753,812 |
| 2021 | 3,125 | 431 | 0% (0) | 23% | $600,657 |
| 2020 | 3,037 | 354 | None | 26% | $482,648 |
| 2019 | 2,916 | 335 | None | 26% | $386,771 |
| 2018 | 2,192 | 252 | None | 20% | $253,310 |
| 2017 | 1,458 | 211 | None | None | $101,743 |
| 2016 | 576 | 118 | 0% (0) | 25% | $46,805 |
| 2015 | 539 | 75 | 0% (0) | None | $26,439 |
| 2014 | 523 | 85 | None | 26% | $24,300 |
| 2013 | 948 | 110 | 15% (137) | None | $63,855 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 50 drugs
| Eliquis | 477 | $508,652 | $1,066 |
| Xarelto | 92 | $121,369 | $1,319 |
| Repatha Sureclick | 162 | $115,347 | $712 |
| Entresto | 67 | $90,441 | $1,350 |
| Multaq | 36 | $52,660 | $1,463 |
| Praluent | 39 | $34,766 | $891 |
| Farxiga | 28 | $26,021 | $929 |
| Nexletol | 16 | $20,037 | $1,252 |
| Nitro-Dur | 11 | $18,687 | $1,699 |
| Brilinta | 11 | $6,146 | $559 |
| Nebivolol | 54 | $5,630 | $104 |
| Rosuvastatin | 172 | $5,489 | $32 |
| Atorvastatin | 347 | $4,731 | $14 |
| Diltiazem 24hr Er (Cd) | 82 | $3,334 | $41 |
| Metoprolol | 211 | $3,142 | $15 |
| Amlodipine Besylate | 363 | $2,693 | $7 |
| Flecainide Acetate | 57 | $2,646 | $46 |
| Amiodarone | 71 | $2,282 | $32 |
| Losartan | 172 | $2,162 | $13 |
| Ezetimibe | 37 | $1,773 | $48 |
| Spironolactone | 124 | $1,492 | $12 |
| Lisinopril | 132 | $1,374 | $10 |
| Furosemide | 204 | $1,348 | $7 |
| Digoxin | 35 | $1,325 | $38 |
| Metoprolol | 165 | $1,252 | $8 |
| Potassium Chloride | 51 | $1,249 | $24 |
| Carvedilol | 113 | $1,187 | $11 |
| Bisoprolol | 14 | $1,138 | $81 |
| Clopidogrel | 44 | $980 | $22 |
| Valsartan | 18 | $874 | $49 |
| Valsartan-Hydrochlorothiazide | 17 | $827 | $49 |
| Diltiazem 24hr Er | 21 | $816 | $39 |
| Prazosin | 17 | $789 | $46 |
| Sotalol | 37 | $661 | $18 |
| Bumetanide | 22 | $651 | $30 |
| Isosorbide Mononitrate Er | 27 | $649 | $24 |
| Hydralazine | 45 | $570 | $13 |
| Diltiazem | 11 | $539 | $49 |
| Diltiazem 24hr Er (Xr) | 12 | $493 | $41 |
| Verapamil Er | 11 | $421 | $38 |
| Pantoprazole | 16 | $376 | $23 |
| Terazosin | 20 | $353 | $18 |
| Minoxidil | 13 | $347 | $27 |
| Ramipril | 16 | $325 | $20 |
| Nitroglycerin | 16 | $274 | $17 |
| Hydrochlorothiazide | 53 | $265 | $5 |
| Clonidine | 20 | $258 | $13 |
| Atenolol | 19 | $255 | $13 |
| Losartan-Hydrochlorothiazide | 17 | $203 | $12 |
| Cephalexin | 13 | $72 | $6 |
2022: 43 drugs
| Eliquis | 383 | $403,808 | $1,054 |
| Xarelto | 91 | $96,784 | $1,064 |
| Repatha Sureclick | 92 | $67,037 | $729 |
| Entresto | 43 | $62,435 | $1,452 |
| Praluent | 23 | $20,167 | $877 |
| Nexletol | 19 | $15,046 | $792 |
| Nebivolol | 69 | $7,164 | $104 |
| Rosuvastatin | 129 | $5,896 | $46 |
| Atorvastatin | 381 | $5,311 | $14 |
| Diltiazem 24hr Er (Cd) | 111 | $3,429 | $31 |
| Metoprolol | 159 | $3,107 | $20 |
| Amlodipine Besylate | 325 | $2,539 | $8 |
| Losartan | 170 | $2,044 | $12 |
| Flecainide Acetate | 37 | $1,604 | $43 |
| Amiodarone | 69 | $1,521 | $22 |
| Diltiazem 24hr Er | 33 | $1,495 | $45 |
| Spironolactone | 127 | $1,482 | $12 |
| Lisinopril | 186 | $1,457 | $8 |
| Carvedilol | 131 | $1,387 | $11 |
| Digoxin | 33 | $1,225 | $37 |
| Ezetimibe | 18 | $1,177 | $65 |
| Furosemide | 218 | $1,135 | $5 |
| Midodrine | 12 | $951 | $79 |
| Bisoprolol | 12 | $931 | $78 |
| Prazosin | 21 | $927 | $44 |
| Metoprolol | 129 | $878 | $7 |
| Hydralazine | 56 | $852 | $15 |
| Valsartan-Hydrochlorothiazide | 14 | $777 | $56 |
| Potassium Chloride | 32 | $764 | $24 |
| Isosorbide Mononitrate Er | 28 | $684 | $24 |
| Sotalol | 22 | $513 | $23 |
| Clopidogrel | 31 | $440 | $14 |
| Bumetanide | 11 | $381 | $35 |
| Levothyroxine | 16 | $379 | $24 |
| Hydrochlorothiazide | 63 | $351 | $6 |
| Nitroglycerin | 20 | $342 | $17 |
| Minoxidil | 11 | $305 | $28 |
| Terazosin | 12 | $273 | $23 |
| Clonidine | 21 | $194 | $9 |
| Benazepril | 15 | $136 | $9 |
| Atenolol | 21 | $133 | $6 |
| Losartan-Hydrochlorothiazide | 20 | $127 | $6 |
| Cephalexin | 14 | $67 | $5 |
2021: 43 drugs
| Eliquis | 288 | $292,313 | $1,015 |
| Xarelto | 77 | $83,561 | $1,085 |
| Repatha Sureclick | 89 | $58,848 | $661 |
| Entresto | 46 | $51,628 | $1,122 |
| Multaq | 15 | $18,229 | $1,215 |
| Bystolic | 28 | $11,321 | $404 |
| Atorvastatin | 347 | $5,909 | $17 |
| Livalo | 12 | $4,789 | $399 |
| Rosuvastatin | 99 | $4,697 | $47 |
| Metoprolol | 170 | $3,868 | $23 |
| Diltiazem 24hr Er (Cd) | 89 | $3,844 | $43 |
| Amlodipine Besylate | 258 | $2,228 | $9 |
| Losartan | 137 | $1,743 | $13 |
| Flecainide Acetate | 25 | $1,657 | $66 |
| Diltiazem 24hr Er | 35 | $1,516 | $43 |
| Carvedilol | 143 | $1,498 | $10 |
| Furosemide | 190 | $1,488 | $8 |
| Amiodarone | 48 | $1,196 | $25 |
| Spironolactone | 102 | $1,176 | $12 |
| Lisinopril | 130 | $1,159 | $9 |
| Midodrine | 19 | $1,079 | $57 |
| Bumetanide | 19 | $1,036 | $55 |
| Dilt-Xr | 12 | $950 | $79 |
| Digoxin | 20 | $895 | $45 |
| Isosorbide Mononitrate Er | 43 | $824 | $19 |
| Metoprolol | 95 | $741 | $8 |
| Hydralazine | 53 | $641 | $12 |
| Potassium Chloride | 24 | $612 | $25 |
| Sotalol | 28 | $600 | $21 |
| Valsartan | 11 | $505 | $46 |
| Ramipril | 13 | $392 | $30 |
| Clonidine | 33 | $370 | $11 |
| Clopidogrel | 23 | $337 | $15 |
| Minoxidil | 12 | $324 | $27 |
| Verapamil Er | 11 | $297 | $27 |
| Pantoprazole | 12 | $268 | $22 |
| Metolazone | 16 | $263 | $16 |
| Nitroglycerin | 15 | $244 | $16 |
| Hydrochlorothiazide | 42 | $211 | $5 |
| Losartan-Hydrochlorothiazide | 13 | $201 | $15 |
| Atenolol | 15 | $150 | $10 |
| Cephalexin | 20 | $145 | $7 |
| Benazepril | 15 | $143 | $10 |
2020: 43 drugs
| Eliquis | 295 | $246,949 | $837 |
| Xarelto | 78 | $70,332 | $902 |
| Entresto | 59 | $45,591 | $773 |
| Repatha Sureclick | 58 | $40,170 | $693 |
| Bystolic | 45 | $12,530 | $278 |
| Atorvastatin | 321 | $5,867 | $18 |
| Metoprolol | 206 | $5,227 | $25 |
| Livalo | 15 | $4,876 | $325 |
| Insulin Lispro | 11 | $4,464 | $406 |
| Rosuvastatin | 82 | $3,987 | $49 |
| Flecainide Acetate | 38 | $2,869 | $76 |
| Diltiazem 24hr Er | 71 | $2,444 | $34 |
| Amlodipine Besylate | 237 | $1,989 | $8 |
| Losartan | 107 | $1,420 | $13 |
| Furosemide | 210 | $1,359 | $6 |
| Diltiazem 24hr Er (Cd) | 43 | $1,305 | $30 |
| Carvedilol | 139 | $1,206 | $9 |
| Dilt-Xr | 13 | $1,192 | $92 |
| Amiodarone | 33 | $1,148 | $35 |
| Lisinopril | 137 | $1,134 | $8 |
| Isosorbide Mononitrate Er | 46 | $981 | $21 |
| Spironolactone | 102 | $880 | $9 |
| Valsartan | 11 | $865 | $79 |
| Valsartan-Hydrochlorothiazide | 15 | $851 | $57 |
| Sotalol | 30 | $814 | $27 |
| Potassium Chloride | 35 | $803 | $23 |
| Metoprolol | 82 | $620 | $8 |
| Metolazone | 21 | $581 | $28 |
| Cartia Xt | 12 | $527 | $44 |
| Verapamil Er | 20 | $484 | $24 |
| Midodrine | 13 | $479 | $37 |
| Sotalol Af | 11 | $410 | $37 |
| Hydrochlorothiazide | 57 | $363 | $6 |
| Clopidogrel | 33 | $343 | $10 |
| Pantoprazole | 24 | $338 | $14 |
| Hydralazine | 29 | $310 | $11 |
| Ramipril | 18 | $306 | $17 |
| Warfarin | 23 | $291 | $13 |
| Nitroglycerin | 17 | $269 | $16 |
| Levothyroxine | 21 | $246 | $12 |
| Clonidine | 14 | $182 | $13 |
| Atenolol | 15 | $127 | $8 |
| Cephalexin | 12 | $65 | $5 |
2019: 42 drugs
| Eliquis | 254 | $179,022 | $705 |
| Xarelto | 78 | $54,869 | $703 |
| Repatha Sureclick | 77 | $39,485 | $513 |
| Entresto | 63 | $36,112 | $573 |
| Brilinta | 17 | $11,604 | $683 |
| Bystolic | 46 | $10,228 | $222 |
| Atorvastatin | 270 | $5,600 | $21 |
| Metoprolol | 213 | $5,175 | $24 |
| Rosuvastatin | 92 | $4,607 | $50 |
| Flecainide Acetate | 36 | $2,191 | $61 |
| Amiodarone | 54 | $2,109 | $39 |
| Amlodipine Besylate | 228 | $1,902 | $8 |
| Carvedilol | 155 | $1,638 | $11 |
| Diltiazem 24hr Er | 41 | $1,375 | $34 |
| Diltiazem 24hr Er (Cd) | 24 | $1,289 | $54 |
| Furosemide | 195 | $1,263 | $6 |
| Losartan | 79 | $1,158 | $15 |
| Isosorbide Mononitrate Er | 68 | $955 | $14 |
| Lisinopril | 120 | $922 | $8 |
| Valsartan | 13 | $819 | $63 |
| Metoprolol | 103 | $714 | $7 |
| Potassium Chloride | 25 | $581 | $23 |
| Bumetanide | 12 | $495 | $41 |
| Digoxin | 14 | $487 | $35 |
| Clopidogrel | 56 | $469 | $8 |
| Spironolactone | 63 | $458 | $7 |
| Sotalol | 13 | $445 | $34 |
| Cartia Xt | 12 | $417 | $35 |
| Hydrochlorothiazide | 71 | $408 | $6 |
| Metolazone | 11 | $359 | $33 |
| Nitroglycerin | 19 | $349 | $18 |
| Nifedipine Er | 12 | $348 | $29 |
| Warfarin | 27 | $307 | $11 |
| Pantoprazole | 33 | $276 | $8 |
| Benazepril | 17 | $255 | $15 |
| Hydralazine | 26 | $230 | $9 |
| Diltiazem | 13 | $192 | $15 |
| Atenolol | 22 | $141 | $6 |
| Simvastatin | 11 | $137 | $12 |
| Losartan-Hydrochlorothiazide | 16 | $106 | $7 |
| Clonidine | 13 | $104 | $8 |
| Cephalexin | 13 | $58 | $4 |
2018: 36 drugs
| Eliquis | 155 | $89,493 | $577 |
| Xarelto | 107 | $64,478 | $603 |
| Repatha Sureclick | 20 | $24,216 | $1,211 |
| Entresto | 12 | $6,422 | $535 |
| Bystolic | 30 | $6,223 | $207 |
| Brilinta | 11 | $5,942 | $540 |
| Atorvastatin | 217 | $4,933 | $23 |
| Rosuvastatin | 108 | $4,237 | $39 |
| Metoprolol | 166 | $3,955 | $24 |
| Carvedilol | 154 | $1,363 | $9 |
| Amlodipine Besylate | 185 | $1,285 | $7 |
| Diltiazem 24hr Er | 17 | $1,158 | $68 |
| Flecainide Acetate | 13 | $1,147 | $88 |
| Amiodarone | 30 | $1,032 | $34 |
| Losartan | 86 | $1,006 | $12 |
| Diltiazem 24hr Er (Cd) | 21 | $886 | $42 |
| Isosorbide Mononitrate Er | 56 | $699 | $12 |
| Metoprolol | 117 | $696 | $6 |
| Ezetimibe | 14 | $667 | $48 |
| Lisinopril | 87 | $576 | $7 |
| Minoxidil | 21 | $506 | $24 |
| Hydralazine | 35 | $498 | $14 |
| Bisoprolol | 21 | $444 | $21 |
| Nitroglycerin | 17 | $401 | $24 |
| Furosemide | 90 | $395 | $4 |
| Hydrochlorothiazide | 55 | $344 | $6 |
| Cartia Xt | 13 | $298 | $23 |
| Potassium Chloride | 17 | $277 | $16 |
| Warfarin | 14 | $276 | $20 |
| Metolazone | 13 | $262 | $20 |
| Clopidogrel | 37 | $255 | $7 |
| Simvastatin | 12 | $179 | $15 |
| Pantoprazole | 26 | $173 | $7 |
| Spironolactone | 15 | $120 | $8 |
| Clonidine | 19 | $115 | $6 |
| Losartan-Hydrochlorothiazide | 18 | $98 | $5 |
2017: 31 drugs
| Eliquis | 70 | $38,668 | $552 |
| Xarelto | 44 | $21,026 | $478 |
| Amiodarone | 48 | $3,052 | $64 |
| Ezetimibe | 11 | $2,993 | $272 |
| Atorvastatin | 126 | $2,464 | $20 |
| Metoprolol | 88 | $2,407 | $27 |
| Rosuvastatin | 71 | $2,339 | $33 |
| Flecainide Acetate | 18 | $1,367 | $76 |
| Digoxin | 23 | $992 | $43 |
| Carvedilol | 124 | $814 | $7 |
| Amlodipine Besylate | 108 | $807 | $7 |
| Isosorbide Mononitrate Er | 42 | $699 | $17 |
| Diltiazem 24hr Er | 18 | $628 | $35 |
| Cartia Xt | 14 | $455 | $32 |
| Bisoprolol | 28 | $436 | $16 |
| Losartan | 44 | $407 | $9 |
| Metoprolol | 69 | $398 | $6 |
| Minoxidil | 29 | $384 | $13 |
| Nitroglycerin | 16 | $368 | $23 |
| Lisinopril | 60 | $365 | $6 |
| Hydralazine | 21 | $358 | $17 |
| Clopidogrel | 11 | $338 | $31 |
| Furosemide | 76 | $327 | $4 |
| Hydrochlorothiazide | 28 | $163 | $6 |
| Losartan-Hydrochlorothiazide | 17 | $149 | $9 |
| Clonidine | 20 | $126 | $6 |
| Simvastatin | 11 | $124 | $11 |
| Pantoprazole | 18 | $110 | $6 |
| Benazepril | 14 | $84 | $6 |
| Ramipril | 14 | $76 | $5 |
| Cephalexin | 12 | $52 | $4 |
2016: 13 drugs
| Eliquis | 54 | $24,592 | $455 |
| Brilinta | 24 | $7,195 | $300 |
| Atorvastatin | 60 | $1,088 | $18 |
| Clopidogrel | 53 | $1,073 | $20 |
| Metoprolol | 44 | $758 | $17 |
| Amiodarone | 11 | $445 | $40 |
| Carvedilol | 34 | $243 | $7 |
| Amlodipine Besylate | 41 | $188 | $5 |
| Metoprolol | 25 | $126 | $5 |
| Losartan | 16 | $91 | $6 |
| Furosemide | 37 | $66 | $2 |
| Spironolactone | 12 | $62 | $5 |
| Lisinopril | 23 | $48 | $2 |
2015: 16 drugs
| Eliquis | 21 | $8,852 | $422 |
| Brilinta | 16 | $4,110 | $257 |
| Crestor | 18 | $3,846 | $214 |
| Atorvastatin | 47 | $609 | $13 |
| Clopidogrel | 67 | $574 | $9 |
| Metoprolol | 24 | $478 | $20 |
| Nitrostat | 12 | $294 | $25 |
| Tamsulosin | 14 | $267 | $19 |
| Amlodipine Besylate | 45 | $210 | $5 |
| Potassium Chloride | 13 | $172 | $13 |
| Carvedilol | 25 | $131 | $5 |
| Lisinopril | 39 | $121 | $3 |
| Metoprolol | 13 | $118 | $9 |
| Furosemide | 35 | $93 | $3 |
| Losartan | 19 | $86 | $5 |
| Spironolactone | 11 | $46 | $4 |
2014: 20 drugs
| Eliquis | 11 | $5,675 | $516 |
| Diovan | 12 | $1,653 | $138 |
| Atorvastatin | 47 | $844 | $18 |
| Felodipine Er | 12 | $506 | $42 |
| Metoprolol | 20 | $491 | $25 |
| Klor-Con 8 | 17 | $455 | $27 |
| Clopidogrel | 45 | $413 | $9 |
| Carvedilol | 26 | $229 | $9 |
| Lisinopril | 38 | $201 | $5 |
| Digoxin | 11 | $179 | $16 |
| Amlodipine Besylate | 28 | $151 | $5 |
| Isosorbide Mononitrate Er | 17 | $146 | $9 |
| Spironolactone | 21 | $115 | $5 |
| Warfarin | 16 | $104 | $6 |
| Benazepril | 16 | $103 | $6 |
| Metoprolol | 18 | $101 | $6 |
| Furosemide | 24 | $94 | $4 |
| Losartan | 15 | $90 | $6 |
| Atenolol | 14 | $58 | $4 |
| Metformin | 11 | $43 | $4 |
2013: 29 drugs
| Cymbalta | 20 | $8,966 | $448 |
| Prandin | 11 | $6,616 | $601 |
| Spiriva | 11 | $5,096 | $463 |
| Crestor | 12 | $2,059 | $172 |
| Hydrocodone-Acetaminophen | 70 | $1,682 | $24 |
| Morphine Sulfate Er | 32 | $1,084 | $34 |
| Omeprazole | 50 | $1,070 | $21 |
| Atorvastatin | 21 | $893 | $43 |
| Proair Hfa | 14 | $698 | $50 |
| Hydromorphone | 11 | $559 | $51 |
| Clopidogrel | 29 | $376 | $13 |
| Venlafaxine Hcl Er | 12 | $347 | $29 |
| Gabapentin | 15 | $289 | $19 |
| Lisinopril | 30 | $221 | $7 |
| Amlodipine Besylate | 29 | $210 | $7 |
| Metformin | 18 | $202 | $11 |
| Tamsulosin | 11 | $190 | $17 |
| Warfarin | 12 | $182 | $15 |
| Levothyroxine | 17 | $165 | $10 |
| Metoprolol | 16 | $135 | $8 |
| Simvastatin | 22 | $134 | $6 |
| Ranitidine | 22 | $132 | $6 |
| Carvedilol | 12 | $124 | $10 |
| Pravastatin | 11 | $124 | $11 |
| Trazodone | 17 | $84 | $5 |
| Atenolol | 15 | $79 | $5 |
| Furosemide | 12 | $76 | $6 |
| Lorazepam | 11 | $53 | $5 |
| Zolpidem | 12 | $48 | $4 |
Money from drug and device companies
$4,185 in 2025
| 2025 | 25 | 151 | None | $4,185 |
| 2024 | 23 | 143 | None | $3,379 |
| 2023 | 23 | 125 | $13 | $3,790 |
| 2022 | 20 | 106 | None | $3,134 |
| 2021 | 24 | 143 | None | $3,788 |
| 2020 | 21 | 127 | None | $2,696 |
| 2019 | 23 | 117 | None | $3,371 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Watchman | $1,060 | 9 payments
|
| Novartis Pharmaceuticals | Leqvio | $563 | 27 payments
|
| Biotronik | Amvia Edge | $315 | 9 payments
|
| Pfizer | Eliquis | $250 | 14 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $246 | 18 payments
|
| Amgen | Repatha | $230 | 14 payments
|
See all 151 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-16 | Jardiance | $30 |
| Amgen | Meals · 2025-12-12 | Repatha | $25 |
| Boston Scientific | Travel · 2025-12-11 | Watchman Access System | $262 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-11 | Eliquis | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-10 | Eliquis | $11 |
| Biotronik | Meals · 2025-12-10 | Amvia Edge | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-09 | Eliquis | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-08 | Kerendia | $22 |
| Pfizer | Meals · 2025-12-05 | Eliquis | $20 |
| Esperion Therapeutics | Meals · 2025-12-05 | Nexletol | $14 |
| Boston Scientific | Travel · 2025-12-04 | Watchman Access System | $71 |
| Amgen | Meals · 2025-12-01 | Repatha | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-24 | Eliquis | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-24 | Eliquis | $6 |
| Amgen | Meals · 2025-11-24 | Repatha | $19 |
| Merck Sharp & Dohme | Meals · 2025-11-21 | Capvaxive | $25 |
| Pfizer | Meals · 2025-11-19 | Eliquis | $16 |
| AtriCure | Meals · 2025-11-17 | Epi-Sense Guided Coagulation System With Visitrax | $26 |
| Esperion Therapeutics | Meals · 2025-11-14 | Nexletol | $18 |
| Novo Nordisk | Meals · 2025-11-13 | Wegovy | $13 |
| GlaxoSmithKline | Meals · 2025-11-13 | Arexvy | $20 |
| Novartis Pharmaceuticals | Meals · 2025-11-11 | Leqvio | $31 |
| Scpharmaceuticals | Meals · 2025-11-07 | Furoscix | $24 |
| Biotronik | Meals · 2025-11-07 | Amvia Edge | $42 |
| Novartis Pharmaceuticals | Meals · 2025-11-05 | Leqvio | $141 |
| Novartis Pharmaceuticals | Meals · 2025-10-28 | Leqvio | $14 |
| Merck Sharp & Dohme | Meals · 2025-10-27 | Capvaxive | $26 |
| Pfizer | Meals · 2025-10-24 | Eliquis | $16 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-23 | Kerendia | $18 |
| Biotronik | Meals · 2025-10-23 | Rivacor 7 Dr-T | $21 |
| Novartis Pharmaceuticals | Meals · 2025-10-21 | Leqvio | $27 |
| Boston Scientific | Meals · 2025-10-18 | Watchman | $294 |
| Boston Scientific | Meals · 2025-10-17 | Watchman | $79 |
| Boston Scientific | Travel · 2025-10-17 | Watchman | $275 |
| Lilly USA | Meals · 2025-10-16 | Mounjaro | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-03 | Eliquis | $25 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $5 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $5 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | Leqvio | $7 |
| Pfizer | Meals · 2025-09-30 | Vyndaqel | $22 |
| Pfizer | Meals · 2025-09-26 | Eliquis | $14 |
| Novo Nordisk | Meals · 2025-09-25 | Wegovy | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-25 | Leqvio | $13 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-09-24 | Lifevest | $12 |
| Merck Sharp & Dohme | Meals · 2025-09-23 | Verquvo | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-18 | Eliquis | $7 |
| Biotronik | Meals · 2025-09-18 | Amvia Edge | $167 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-17 | Kerendia | $23 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-09-16 | Lifevest | $22 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Leqvio | $9 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-09 | Eliquis | $21 |
| Biotronik | Meals · 2025-08-28 | Amvia Edge | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-27 | Kerendia | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | Leqvio | $4 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-26 | Jardiance | $15 |
| Abiomed | Meals · 2025-08-24 | None | $120 |
| Pfizer | Meals · 2025-08-22 | Eliquis | $18 |
| Amgen | Meals · 2025-08-21 | Repatha | $10 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Leqvio | $9 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Leqvio | $9 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-18 | Lifevest | $17 |
| Amgen | Meals · 2025-08-14 | Repatha | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-12 | Eliquis | $4 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-12 | Eliquis | $23 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Leqvio | $8 |
| Merck Sharp & Dohme | Meals · 2025-08-11 | Verquvo | $30 |
| Novo Nordisk | Meals · 2025-08-10 | Wegovy | $21 |
| Baxter Healthcare | Meals · 2025-08-07 | Hillrom - Carnation Ambulatory Monitor | $33 |
| Novo Nordisk | Meals · 2025-08-07 | Wegovy | $22 |
| Amgen | Meals · 2025-08-07 | Repatha | $24 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Leqvio | $0 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Leqvio | $19 |
| Pfizer | Meals · 2025-08-01 | Vyndaqel | $24 |
| Abiomed | Meals · 2025-07-30 | None | $50 |
| Novo Nordisk | Meals · 2025-07-26 | Wegovy | $21 |
| Amgen | Meals · 2025-07-15 | Repatha | $8 |
| Abbott Laboratories | Meals · 2025-07-15 | Cardiomems | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-10 | Eliquis | $9 |
| BridgeBio Pharma | Meals · 2025-07-09 | Attruby | $27 |
| Novartis Pharmaceuticals | Meals · 2025-07-08 | Leqvio | $4 |
| Heartflow | Meals · 2025-07-07 | Ffrct | $31 |
| Novartis Pharmaceuticals | Meals · 2025-06-30 | Leqvio | $10 |
| Scpharmaceuticals | Meals · 2025-06-27 | Furoscix | $19 |
| Pfizer | Meals · 2025-06-26 | Eliquis | $19 |
| Cordis US | Meals · 2025-06-23 | Mynx Control Venous | $18 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-20 | Lifevest | $12 |
| Biotronik | Meals · 2025-06-19 | Biomonitor | $15 |
| Amgen | Meals · 2025-06-17 | Repatha | $24 |
| Edwards Lifesciences | Meals · 2025-06-11 | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $52 |
| Novartis Pharmaceuticals | Meals · 2025-06-10 | Leqvio | $8 |
| Merck Sharp & Dohme | Meals · 2025-06-09 | Verquvo | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-02 | Farxiga | $32 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-28 | Lifevest | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-28 | Camzyos | $10 |
| Boston Scientific | Meals · 2025-05-27 | Watchman Flx | $33 |
| Esperion Therapeutics | Meals · 2025-05-23 | Nexletol | $17 |
| Novo Nordisk | Meals · 2025-05-22 | Wegovy | $6 |
| Novo Nordisk | Meals · 2025-05-22 | Wegovy | $6 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-19 | Lifevest | $23 |
| Pfizer | Meals · 2025-05-16 | Eliquis | $15 |
| Novartis Pharmaceuticals | Meals · 2025-05-14 | Leqvio | $9 |
| Amgen | Meals · 2025-05-13 | Repatha | $24 |
| Novartis Pharmaceuticals | Meals · 2025-05-09 | Leqvio | $8 |
| Pfizer | Meals · 2025-05-09 | Vyndaqel | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-08 | Kerendia | $33 |
| Novo Nordisk | Meals · 2025-05-02 | Wegovy | $10 |
| Amgen | Meals · 2025-05-01 | Repatha | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-29 | Jardiance | $21 |
| Novo Nordisk | Meals · 2025-04-28 | Wegovy | $21 |
| Pfizer | Meals · 2025-04-25 | Eliquis | $15 |
| Novartis Pharmaceuticals | Meals · 2025-04-24 | Leqvio | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Eliquis | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Eliquis | $2 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-22 | Farxiga | $19 |
| Amgen | Meals · 2025-04-22 | Repatha | $20 |
| Boston Scientific | Meals · 2025-04-18 | Watchman Flx | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-16 | Eliquis | $7 |
| Novartis Pharmaceuticals | Meals · 2025-04-16 | Leqvio | $3 |
| Merck Sharp & Dohme | Meals · 2025-04-14 | Verquvo | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-02 | Eliquis | $20 |
| Novartis Pharmaceuticals | Meals · 2025-04-01 | Leqvio | $140 |
| Alnylam Pharmaceuticals | Meals · 2025-03-31 | Amvuttra | $20 |
| Pfizer | Meals · 2025-03-27 | Vyndaqel | $17 |
| Abbott Laboratories | Meals · 2025-03-27 | Cardiomems | $19 |
| Amgen | Meals · 2025-03-26 | Repatha | $10 |
| Novo Nordisk | Meals · 2025-03-25 | Wegovy | $21 |
| Novartis Pharmaceuticals | Meals · 2025-03-24 | Leqvio | $6 |
| Biotronik | Meals · 2025-03-24 | Renamic Neo | $6 |
| Heartflow | Meals · 2025-03-19 | Ffrct | $167 |
| Novo Nordisk | Meals · 2025-03-18 | Wegovy | $13 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | Leqvio | $8 |
| Pfizer | Meals · 2025-03-13 | Eliquis | $16 |
| Heartflow | Meals · 2025-03-13 | Ffrct | $21 |
| Amgen | Meals · 2025-03-07 | Repatha | $22 |
| Biotronik | Meals · 2025-03-06 | Biomonitor | $22 |
| Novartis Pharmaceuticals | Meals · 2025-03-04 | Leqvio | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-26 | Camzyos | $22 |
| Merck Sharp & Dohme | Meals · 2025-02-24 | Verquvo | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-14 | Camzyos | $10 |
| Pfizer | Meals · 2025-02-14 | Eliquis | $16 |
| Boston Scientific | Meals · 2025-02-11 | Watchman Flx | $19 |
| Amgen | Meals · 2025-02-07 | Repatha | $19 |
| Novartis Pharmaceuticals | Meals · 2025-02-06 | Leqvio | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-05 | Jardiance | $19 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Leqvio | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-04 | Farxiga | $22 |
| Biotronik | Meals · 2025-01-28 | Biomonitor | $12 |
| Novartis Pharmaceuticals | Meals · 2025-01-22 | Leqvio | $9 |
| Merck Sharp & Dohme | Meals · 2025-01-16 | Verquvo | $26 |
| Boston Scientific | Meals · 2025-01-15 | Watchman Flx | $14 |
| Esperion Therapeutics | Meals · 2025-01-13 | Nexletol | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,379
| Abbott Laboratories | Cardiomems | $634 | 13 payments
|
| Novartis Pharmaceuticals | Leqvio | $522 | 24 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $290 | 13 payments
|
| Merck Sharp & Dohme | Verquvo | $268 | 11 payments
|
| Amgen | Repatha | $211 | 13 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $156 | 10 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $153 | 1 payment
|
| Esperion Therapeutics | Nexletol | $149 | 9 payments
|
| Boston Scientific | Watchman Flx | $139 | 8 payments
|
| Pfizer | Eliquis | $137 | 8 payments
|
| Sanofi-Aventis U.S. | Multaq | $135 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $103 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $94 | 5 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $67 | 3 payments
|
| Novo Nordisk | Rybelsus | $59 | 3 payments
|
| Heartflow | Ffrct | $56 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $45 | 2 payments
|
| Biotronik | Amvia Edge | $44 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $33 | 1 payment
|
| Regeneron Healthcare Solutions | Evkeeza | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $22 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $19 | 1 payment
|
| Lexicon Pharmaceuticals | None | $19 | 1 payment
|
2023: $3,790
| Abbott Laboratories | Cardiomems | $694 | 7 payments
|
| Novartis Pharmaceuticals | Leqvio | $422 | 16 payments
|
| Boston Scientific | Watchman Flx | $320 | 7 payments
|
| Merck Sharp & Dohme | Verquvo | $307 | 11 payments
|
| Amgen | Repatha | $289 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $238 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $164 | 8 payments
|
| Philips Electronics North America | (6574) Coronary Other | $158 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $158 | 7 payments
|
| Pfizer | Eliquis | $156 | 9 payments
|
| GE HealthCare | None | $156 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $154 | 6 payments
|
| Esperion Therapeutics | Nexletol | $111 | 5 payments
|
| Atricure | Atriclip Laa Exclusion System | $103 | 3 payments
|
| Terumo Medical | Heartrail | $67 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $64 | 3 payments
|
| Sanofi-Aventis U.S. | Multaq | $52 | 3 payments
|
| Alnylam Pharmaceuticals | Onpattro | $48 | 2 payments
|
| Biosense Webster | None | $32 | 1 payment
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $32 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $31 | 1 payment
|
| Regeneron Healthcare Solutions | Evkeeza | $29 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $7 | 1 payment
|
2022: $3,134
| Abbott Laboratories | Cardiomems | $780 | 13 payments
|
| Biotronik | Rivacor 7 Dr-T | $372 | 7 payments
|
| Amgen | Repatha | $292 | 6 payments
|
| Bard Peripheral Vascular | Lutonix Drug Coated Balloon | $224 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $213 | 16 payments
|
| Janssen Pharmaceuticals | Xarelto | $197 | 10 payments
|
| Merck Sharp & Dohme | Verquvo | $187 | 10 payments
|
| Actelion Pharmaceuticals US | Uptravi | $146 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $131 | 8 payments
|
| Pfizer | Eliquis | $125 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $104 | 6 payments
|
| Alnylam Pharmaceuticals | Onpattro | $81 | 3 payments
|
| Esperion Therapeutics | Nexletol | $62 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $46 | 2 payments
|
| iRhythm Technologies | Zio Xt Patch | $38 | 2 payments
|
| Boston Scientific | Watchman Access System | $33 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $31 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $31 | 1 payment
|
| Astellas Pharma US | Lexiscan | $23 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $17 | 1 payment
|
2021: $3,788
| Abbott Laboratories | Cardiomems Hf System | $948 | 16 payments
|
| Biotronik | Edora | $496 | 8 payments
|
| Amgen | Repatha | $450 | 14 payments
|
| Boston Scientific | General - Vascular Access | $332 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $189 | 10 payments
|
| Janssen Pharmaceuticals | Xarelto | $185 | 15 payments
|
| Novartis Pharmaceuticals | Entresto | $179 | 14 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $167 | 6 payments
|
| Merck Sharp & Dohme | Verquvo | $166 | 9 payments
|
| Actelion Pharmaceuticals US | Uptravi | $107 | 5 payments
|
| Pfizer | Eliquis | $90 | 5 payments
|
| Amarin Pharma | Vascepa | $81 | 4 payments
|
| Kowa Pharmaceuticals America | Livalo | $72 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $69 | 4 payments
|
| Kiniksa Pharmaceuticals | None | $61 | 3 payments
|
| Sanofi-Aventis U.S. | Multaq | $37 | 2 payments
|
| Medtronic | Reveal Linq | $29 | 2 payments
|
| Esperion Therapeutics | Nexletol | $23 | 2 payments
|
| Lundbeck | Northera | $23 | 1 payment
|
| HeartFlow | Ffrct | $20 | 1 payment
|
| Medicure Pharma | Zypitamag | $19 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $19 | 1 payment
|
| Ethicon US | Stratafix | $16 | 1 payment
|
| Astellas Pharma US | Lexiscan | $12 | 1 payment
|
2020: $2,696
| Abbott Laboratories | Cardiomems Hf System | $452 | 6 payments
|
| Amarin Pharma | Vascepa | $319 | 16 payments
|
| Amgen | Repatha | $284 | 12 payments
|
| Biotronik | None | $243 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $213 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $168 | 8 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $157 | 7 payments
|
| Shockwave Medical | Vascular Lithotripsy | $131 | 1 payment
|
| Esperion Therapeutics | Nexletol | $128 | 15 payments
|
| Novartis Pharmaceuticals | Entresto | $119 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $82 | 4 payments
|
| Kowa Pharmaceuticals America | Livalo | $74 | 4 payments
|
| Philips Electronics North America | (7999) Src Undivided | $74 | 1 payment
|
| Lundbeck | Northera | $58 | 3 payments
|
| Pfizer | Chantix | $52 | 3 payments
|
| Medtronic Vascular | Micra | $51 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $22 | 1 payment
|
| Boston Scientific | Watchman | $22 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $17 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $17 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $14 | 1 payment
|
2019: $3,371
| Biotronik | None | $856 | 10 payments
|
| Amgen | Repatha | $354 | 15 payments
|
| Novartis Pharmaceuticals | Entresto | $321 | 16 payments
|
| Janssen Pharmaceuticals | Xarelto | $204 | 12 payments
|
| Abbott Laboratories | Cardiomems Hf System | $194 | 2 payments
|
| Akcea Therapeutics | Tegsedi | $164 | 4 payments
|
| Actelion Pharmaceuticals US | Uptravi | $145 | 9 payments
|
| Regeneron Healthcare Solutions | Praluent | $137 | 10 payments
|
| Radius Health | Tymlos | $125 | 1 payment
|
| Biosense Webster | Carto 3 System | $125 | 1 payment
|
| Amarin Pharma | Vascepa | $114 | 8 payments
|
| Lundbeck | Northera | $109 | 5 payments
|
| Sanofi-Aventis U.S. | Praluent | $83 | 5 payments
|
| Gilead Sciences | Letairis | $67 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $64 | 3 payments
|
| Pfizer | Eliquis | $64 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $61 | 3 payments
|
| Boston Scientific | Rhythmia | $55 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $45 | 1 payment
|
| Cardiovascular Systems | Peripheral Orbital Atherectomy System | $27 | 1 payment
|
| Astellas Pharma US | Lexiscan | $24 | 1 payment
|
| Aegerion Pharmaceuticals | Juxtapid | $17 | 1 payment
|
| Medtronic Vascular | Reveal Linq | $15 | 1 payment
|
Checkups this office reported
20 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 83.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 100% | 41 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 99%That's most of the people this applied to. | 1,007 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 65%That's more than half. | 553 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 0%That's few of the people this applied to. Better on this measure. | 161 |
| Breast cancer screeningEligible women who got a mammogram | 27%That's less than half. | 407 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 41%That's less than half. | 312 |
| Checked for fall riskOlder patients screened for fall risk | 100%That's most of the people this applied to. | 850 |
| Colon cancer screeningEligible adults who got a colon cancer test | 25%That's less than half. | 902 |
See the other 12 measures
| Daily function assessedPatients whose ability to manage daily activities was assessed | 0%That's few of the people this applied to. | 81 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 100%That's most of the people this applied to. | 1,391 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 2%That's few of the people this applied to. | 52 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 33%That's less than half. Better on this measure. | 52 |
| HIV screeningEligible patients who were screened for HIV | 13%That's few of the people this applied to. | 687 |
| Medications listed in the chartVisits where the current medication list was documented | 97%That's most of the people this applied to. | 3,514 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 637 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 825 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 2%That's few of the people this applied to. Better on this measure. | 890 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 30% | 1,657 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 84%That's most of the people this applied to. | 537 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 34%That's less than half. | 1,494 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Improved the patient portal
- Offers telehealth visits
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports immunizations to the state registry
Professional record
- NPI
- 1407172562
- Licence
- CA A118154California A118154: Current · expires 2027-03-31
- Trained
- University of California, Davis School of Medicine, 2010
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 4860 Y St, Suite 0200, Sacramento, CA, 95817
- NPI first listed
- 2010-04-14
- NPI last updated
- 2013-07-10
This is when the NPI record was last certified, not a medical board exam.